Baylor Heart and Vascular Institute
Dallas, Texas, 75226, United States
NCT Number: NCT02332070
1. To examine two main predictor variables independently and then jointly in stratified and multivariate analyses for the outcomes of CSA-AKI, MARCE, need for RRT, and inpatient mortality, and the composite, as well as the outcomes of 30 day rehospitalization or death, and finally for the days out of hospital and alive adjusted to person-year of time
1. Days from coronary angiogram performed with IOCM to cardiac surgery (1, 2, 3, etc) 2. Thakar Acute Renal Failure (ARF) score (1 to 17) 2. To examine the interrelationships between time in days between angiogram and surgery and the ARF Score with the Society of Thoracic Surgery (STS) Risk score for mortality
Looking for future studies?
Notify MeAll sexes
Observational
Dallas, Texas, 75226, United States
Background: Despite advances in cardiac surgical techniques, modern anesthesia, and adjunctive medical therapies, cardiac-surgery associated acute kidney injury (CSA-AKI) remains a frequent and important complication. With advancing age and more severe comorbidities present in patients undergoing cardiac surgery, multivariate scores (e.g. Thakar Acute Renal Failure [ARF] score) would anticipate future higher rates of CSA-AKI that resolve, lead to progressive chronic kidney disease (CKD), require renal replacement therapy (RRT), and are associated major adverse cardiac events with early and later mortality. Mehta and colleagues in a study of 2441 cases suggested that CSA-AKI was associated with the time between the diagnostic coronary angiogram and the subsequent surgery. This suggested that superimposed risk of contrast-induced AKI (CI-AKI) followed by cardiac surgery was a serial insult to the kidneys producing the clinical syndrome of CSA-AKI. However, Andersen and coworkers, in a study of 285 consecutive patients concluded that cardiac surgery within 1-3 days of coronary angiography was safe and not associated with CSA-AKI. Attempts at evaluating CSA-AKI risk prediction models have been limited by small sample sizes. For example, Kiers et el attempted to evaluate 8 CSA-AKI risk models in 1388 patients and found several scores could not be computed due to lack of information and those that could have unstable point estimates for C-statistics and other measures. As a result, CSA-AKI risk scores and attempts to improve quality of care have not been applied in a widespread manner to cardiac surgical cases. Thus we propose to evaluate these key concepts in a large dataset which captures important clinical events such as CI-AKI and type of contrast used followed by CSA-AKI and associated major adverse renal and cardiac events (MARCE) including the need for RRT, myocardial infarction, stroke, heart failure, hospitalizations (cardiac or renal) and death. We aim to derive a practical approach in determining the optimal waiting period from the time of angiography to cardiac surgery according to risk for CSA-AKI in subjects who have received iso-osmolar contrast media (IOCM) with preoperative angiography, as that agent has been shown to have the lowest risk of CI-AKI.
Specific Aims:
Methods
Study Design: Retrospective cohort
Subjects: Using the Texas Quality Initiative cardiothoracic surgery database, patients who have recorded one preoperative and at least one postoperative serum creatinine (mg/dl).
Excluded Cases
Measurements:
GFR = 141 X min(Scr/κ,1)α X max(Scr/κ,1)-1.209 X 0.993Age X 1.018 [if female] X 1.159 [if black]
Where Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
coronary artery bypass surgery and or cardiac valve surgery with cardiopulmonary bypass
Time frame: 7 days
KDIGO definition
Time frame: 7 days
KDIGO definition
Time frame: 30 days
Composite of need for renal replacement therapy, myocardial infarction, stroke, heart failure, hospitalizations for cardiac reasons, hospitalization for renal reasons, and death
Time frame: 30 days
at least one session of peritoneal dialysis ultrafiltration, hemodialysis, or other form of extracorporeal blood purification
Time frame: 30 days
Myocardial infarction as defined by STS
Time frame: 30 days
Stroke as defined by STS
Time frame: 30 days
Heart failure
Time frame: 30 days
Hospitalization for renal reasons
Time frame: 30 days
Hospitalization for cardiac reaons
Time frame: 30 days
Death
Time frame: 30 days
All-cause hospitalization, emergency room, and observation unit visits at 30 days, and one-year will be obtained from the Dallas-Fort Worth Hospital Council Education and Research (DFWHC) connected a regional enterprise master person index (REMPI) database
Time frame: 1 year
Days out of the hospital and alive will be derived as the converse of death and hospitalized days and will be adjusted to 100 PY of time exposure
Baylor Research Institute
Other
Timing of Coronary Angiography and Multivariate Risk for Cardiac Surgery Associated Acute Kidney Injury and Major Adverse Renal and Cardiac Events (MARCE)
Acronym: MARCE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05990660
Acute Kidney Injury, Female Urogenital Diseases
Krakow, Bielsko-Biata, Poland
View Trial DetailsNCT04788394
AKI, Acute Kidney Injury
Doha, Qatar
View Trial DetailsNCT03632915
Acute Kidney Injury, Female Urogenital Diseases
Baltimore, Maryland, United States
View Trial DetailsNCT03095391
Acute Kidney Injury, Chronic Disease
Birmingham, Alabama, United States
View Trial Details